Table 4 Clinical characteristics of patients with WHO-defined essential thrombocythemia (ET) compared with WHO-defined prefibrotic primary myelofibrosis (prePMF) at presentation as derived from the BCSH-confirmed ET cohort
WHO-defined ET 3 | WHO-defined prePMF 3 | P-value | |
|---|---|---|---|
General characteristics | |||
n | 141 | 77 | |
Age at diagnosis (years) | 58.9 (18.8–88.8) | 64.6 (23.2–88.1) | 0.086 |
Sex male/female | 58/83 | 27/50 | 0.486 |
Clinical characteristics a | |||
Platelets (G/L) | 725 (452–1836) | 840 (457–2530) | 0.012 |
Hemoglobin (g/dl) | 14.5 (11.5–17.3) | 13.9 (8.6–16.6) | 0.007 |
Hematocrit (%) | 43.0 (33.2–52.0) | 41.6 (27.5–48.9) | 0.036 |
WBC (G/L) | 8.8 (2.2–21.1) | 10.3 (4.0–31.3) | 0.004 |
LDH (U/L) | 209 (110–763) | 270 (136–598) | <0.001 |
Palpable splenomegaly (141/77)b | 9.9% (14) | 23.4% (18) | 0.009 |
Fibrosis grading ⩾1 | 0.0% (0) | 20.8% (16) | <0.001 |
Molecular characteristics | |||
Pathogenetic mutation present (141/77)b | 100% (141) | 100% (77) | – |
JAK2 V617F (141/77)b | 78.0% (110) | 61.0% (47) | 0.011 |
CALR (99/65)b | 19.2% (27) | 35.1% (27) | 0.013 |
MPL (33/37)b | 2.8% (4) | 3.9% (3) | 0.700 |
Symptoms at diagnosis | |||
Constitutional symptoms (111/71)b | 15.8% (16) | 20.3% (10) | 1.000 |
Weight loss | 3.6% (4) | 7.0% (5) | 0.315 |
Night sweats | 8.1% (9) | 4.2% (3) | 0.372 |
Fatigue | 5.4% (6) | 5.6% (4) | 1.000 |
Pruritus (111/71)b | 1.8% (2) | 1.4% (1) | 1.000 |
Cytoreductive therapy (108/63) b | |||
Hydroxyurea | 45.4% (49) | 38.1% (24) | 0.423 |
Interferon-alpha | 31.5% (34) | 34.9% (22) | 0.736 |
Anagrelide | 33.3% (36) | 28.6% (18) | 0.610 |
JAK1/2-Inhibitor | 4.6% (5) | 6.3% (4) | 0.727 |
Busulfan | 1.9% (2) | 3.2% (2) | 0.626 |
Othersc | 0.9% (1) | 6.3% (4) | 0.062 |
Antithrombotic therapy with low-dose aspirin (106/63)b | 89.6% (95) | 88.9% (56) | 1.000 |
